Showing results (1011-1020 of 1,069) with videos related to

Sort By:
Pageof 107
European Urology|January 4, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell CarcinomaOscar Reig Torras, Akhilesh Mishra, Alana Christie, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effectsJ M Witkin, J A Monn, J Li, et al.
American Journal of Epidemiology|September 1, 2012
Patterns of 12-year change in physical activity levels in community-dwelling older women: can modest levels of physical activity help older women live longer?Qian-Li Xue, Karen Bandeen-Roche, Thelma J Mielenz, et al.
Clinical Genitourinary Cancer|December 25, 2025
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing TherapyMonica S Nair, Jessica Scarborough, Chandana A Reddy, et al.
Nature|December 2, 1999
Kainate receptors are involved in synaptic plasticityZ A Bortolotto, V R Clarke, C M Delany, et al.
Nature|October 23, 1997
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmissionV R Clarke, B A Ballyk, K H Hoo, et al.
Journal for Immunotherapy of Cancer|January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
The Journal of Urology|December 19, 2008
Long-term impact of a robot assisted laparoscopic prostatectomy mini fellowship training program on postgraduate urological practice patternsAldrin Joseph R Gamboa, Rosanne T Santos, Eric R Sargent, et al.
Molecular Carcinogenesis|January 25, 2002
Proteomic analysis of human prostate cancerMamoun Ahram, Carolyn J M Best, Michael J Flaig, et al.
The Lancet. Oncology|August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 studyMoshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Pageof 107